y*****l
发帖数: 5997 | 1 股票:ARNA, VRTX, ATHX, BDSI, CTIC, BCRX, SGEN
http://finviz.com/screener.ashx?v=341&t=ARNA,VRTX,ATHX,BDSI,CTIC,BCRX,SGEN
http://www.thestreet.com/story/10849406/1/biotech-calendar-key-dates-for-september.html
To prepare, here is a calendar of important, potentially stock-moving
biotech events in September:
Phase III or pivotal registration studies that could report results in
September:
* Vertex Pharmaceuticals'(VRTX) hepatitis C drug telaprevir (previously
treated patients.)
* Seattle Genetics'(SGEN) SGN-33 in acute myeloid leukemia and
brentuximab in Hodgkin's lymphoma.
Sept. 7
FDA advisory panel meeting to review Forest Lab's(FRX) antibiotic
ceftaroline for skin and soft tissue infections.
Sept. 10
BioDelivery Sciences(BDSI): Presentation of full dataset from a phase II
study of BEMA Buprenorphine at Pain Week 2010 conference.
Sept. 11
FDA approval decision: Questcor Pharmaceuticals'(QCOR) Acthar gel in seizure
disorders.
Sept. 12-15
Interscience Conference on Antimicrobial Agents and Chemotherapy annual
meeting. Expect data from Optimer Pharmaceuticals(OPTR) (fidaxomicin),
Cubist Pharmaceuticals(CBST) (CXA-101) and GlaxoSmithKline(GSK) (GSK2248761).
Rodman & Renshaw Annual Global Investment Conference
Sept. 13-14
Morgan Stanley Global Healthcare Conference
Sept. 14
FDA approval decision: Savient Pharmaceuticals'(SVNT) Krystexxa for gout.
Sept. 14-15
Baird 2010 Health Care Conference
Sept. 15
FDA advisory panel meeting: Abbott Labs'(ABT) obesity drug Meridia (safety
review).
Sept. 16
FDA advisory panel meetings: Arena Pharmaceuticals'(ARNA) lorcaserin in
obesity and Alkermes'(ALKS) Vivitrol Opioid for opioid addiction.
FDA approval decision: AstraZeneca's(AZN) blood thinner Brilinta.
Biocryst Pharmaceuticals(BCRX) analyst/investor meeting.
Cell Therapeutics(CTIC) annual shareholders meeting
Sept. 18-22
European Respiratory Society meeting. Investor-worthy data presentations
include Theravance(THRX) and GlaxoSmithKline (Relovair) and Intermune(ITMN)
(pirfenidone).
Sept. 20-22
UBS Global Life Sciences Conference
Sept. 20-24
European Association for the Study of Diabetes meeting. Watch for data
presentations by Sanofi-Aventis(SNY) (lixisenatide), Bristol-Myers Squibb(
BMY) and AstraZeneca (dapaglifozin) and Novo Nordisk(NVO) (Degludec).
Sept. 21
FDA approval decision: Novartis'(NVS) multiple sclerosis drug Gilenia.
Sept. 21-25
Transcatheter Cardiovascular Therapeutics conference. Watch for data from
Athersys(ATHX) (Multistem).
Sept. 27-28
JMP Securities Healthcare Conference | m*********n
发帖数: 6098 | | y*****l
发帖数: 5997 | 3 大家看看有什么好的吧。
Sept. 12-15 骡马大会
Interscience Conference on Antimicrobial Agents and Chemotherapy annual meeting. Expect data from Optimer Pharmaceuticals(OPTR) (fidaxomicin), Cubist Pharmaceuticals(CBST) (CXA-101) and GlaxoSmithKline(GSK) (GSK2248761).
Rodman & Renshaw Annual Global Investment Conference
【在 m*********n 的大作中提到】
: 置顶一个月吧
| m*********n
发帖数: 6098 | 4 rodm今天跌了居然, 還能進嗎?
bdsi 是黑莊嗎? |
|
